RESEARCH & DEVELOPMENT
Clinical Studies
External trigeminal nerve stimulation (eTNS) therapy has been shown to be an effective migraine treatment in many clinical studies. Following are selected summaries of studies conducted with the CEFALY neuromodulation device.
The De Novo study: Daily eTNS treatment with CEFALY significantly reduces migraine days
The open-label Transcutaneous Supraorbital Neurostimulation in "De Novo" Patients With Migraine Without Aura study evaluated both the safety and efficacy of a brief period of transcutaneous supraorbital neurostimulation (tSNS) in a group of patients with migraine without aura (MwoA).
● 81% of patients saw at least a 50% reduction in monthly migraine attacks.
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
Read the study
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
The ACME study: eTNS is a safe and effective acute treatment for migraine
In the Acute Migraine Therapy with External Trigeminal Neurostimulation (ACME) study, patients saw a reduction in migraine pain intensity following a 60-minute ACUTE treatment session with CEFALY.
● 59% reduction in migraine pain intensity, on average, following one hour of treatment with CEFALY. This relief continued up to 24 hours.
● 79% of acute migraine sufferers saw pain relief.
● 32% of acute migraine sufferers saw pain freedom.
Read the study
● 79% of acute migraine sufferers saw pain relief.
● 32% of acute migraine sufferers saw pain freedom.
The TEAM study: eTNS relieves pain and other migraine symptoms
The Trial of eTNS for the Acute treatment of Migraine (TEAM) study found that the use of self-administered 2-hour eTNS therapy with CEFALY is a safe and effective therapeutic option, with or without the use of acute anti-migraine medications.
● 25.5% of CEFALY users reported pain freedom after 2 hours of treatment.
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
Read the study
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
The PREMICE study: CEFALY eTNS treatment significantly decreases the number of migraine days
With compliant use of CEFALY’s 20-minute PREVENT treatment, patients experienced a significant reduction in the number of migraine days, the Migraine Prevention with a Supraorbital Transcutaneous Stimulator (PREMICE) study found.
● 38.1% of CEFALY users saw at least a 50% reduction in the number of migraine days.
● 30% (mean 2.06) reduction in migraine days in verum group.
Read the study
● 30% (mean 2.06) reduction in migraine days in verum group.
The sedative effect study: Neurostimulation with CEFALY induces fatigue
In this double-blind cross-over sham-controlled study, researchers observed a statistically significant decrease in vigilance and attention during high-frequency neurostimulation. This can be a positive side effect of CEFALY for people suffering an acute migraine attack.
COMING SOON
Stay tuned for future studies!
The De Novo study: Daily eTNS treatment with CEFALY significantly reduces migraine days
The open-label Transcutaneous Supraorbital Neurostimulation in "De Novo" Patients With Migraine Without Aura study evaluated both the safety and efficacy of a brief period of transcutaneous supraorbital neurostimulation (tSNS) in a group of patients with migraine without aura (MwoA).
● 81% of patients saw at least a 50% reduction in monthly migraine attacks.
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
Read the study
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
The sedative effect study: Neurostimulation with CEFALY induces fatigue
In this double-blind cross-over sham-controlled study, researchers observed a statistically significant decrease in vigilance and attention during high-frequency neurostimulation. This can be a positive side effect of CEFALY for people suffering an acute migraine attack.
The ACME study: eTNS is a safe and effective acute treatment for migraine
In the Acute Migraine Therapy with External Trigeminal Neurostimulation (ACME) study, patients saw a reduction in migraine pain intensity following a 60-minute ACUTE treatment session with CEFALY.
● 59% reduction in migraine pain intensity, on average, following one hour of treatment with CEFALY. This relief continued up to 24 hours.
● 79% of acute migraine sufferers saw pain relief.
● 32% of acute migraine sufferers saw pain freedom.
Read the study
● 79% of acute migraine sufferers saw pain relief.
● 32% of acute migraine sufferers saw pain freedom.
The TEAM study: eTNS relieves pain and other migraine symptoms
The Trial of eTNS for the Acute treatment of Migraine (TEAM) study found that the use of self-administered 2-hour eTNS therapy with CEFALY is a safe and effective therapeutic option, with or without the use of acute anti-migraine medications.
● 25.5% of CEFALY users reported pain freedom after 2 hours of treatment.
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
Read the study
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
The PREMICE study: CEFALY eTNS treatment significantly decreases the number of migraine days
With compliant use of CEFALY’s 20-minute PREVENT treatment, patients experienced a significant reduction in the number of migraine days, the Migraine Prevention with a Supraorbital Transcutaneous Stimulator (PREMICE) study found.
● 38.1% of CEFALY users saw at least a 50% reduction in the number of migraine days.
● 30% (mean 2.06) reduction in migraine days in verum group.
Read the study
● 30% (mean 2.06) reduction in migraine days in verum group.
MORE COMING SOON
Check back soon!
Stay tuned for future studies!
The ACME study: eTNS is a safe and effective acute treatment for migraine
In the Acute Migraine Therapy with External Trigeminal Neurostimulation (ACME) study, patients saw a reduction in migraine pain intensity following a 60-minute ACUTE treatment session with CEFALY.
● 59% reduction in migraine pain intensity, on average, following one hour of treatment with CEFALY. This relief continued up to 24 hours.
● 79% of acute migraine sufferers saw pain relief
● 32% of acute migraine sufferers saw pain freedom
Read More
● 59% reduction in migraine pain intensity, on average, following one hour of treatment with CEFALY. This relief continued up to 24 hours.
● 79% of acute migraine sufferers saw pain relief
● 32% of acute migraine sufferers saw pain freedom
The TEAM study: eTNS relieves pain and other migraine symptoms
The Trial of eTNS for the Acute treatment of Migraine (TEAM) study found that the use of self-administered 2-hour eTNS therapy with CEFALY is a safe and effective therapeutic option, with or without the use of acute anti-migraine medications.
● 25.5% of CEFALY users reported pain freedom after 2 hours of treatment.
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
Read More
● 25.5% of CEFALY users reported pain freedom after 2 hours of treatment.
● 56.4% of CEFALY users reported resolution of their most bothersome migraine symptom.
● 42.5% of CEFALY users reported resolution of all migraine symptoms.
The PREMICE study: CEFALY eTNS treatment significantly decreases the number of migraine days
With compliant use of CEFALY’s 20-minute PREVENT treatment, patients experienced a significant reduction in the number of migraine days, the Migraine Prevention with a Supraorbital Transcutaneous Stimulator (PREMICE) study found.
● 38.1% of CEFALY users saw at least a 50% reduction in the number of migraine days.
● 30% (mean 2.06) reduction in migraine days in verum group.
Read More
● 38.1% of CEFALY users saw at least a 50% reduction in the number of migraine days.
● 30% (mean 2.06) reduction in migraine days in verum group.
The De Novo study: Daily eTNS treatment with CEFALY significantly reduces migraine days
The open-label Transcutaneous Supraorbital Neurostimulation in "De Novo" Patients With Migraine Without Aura study evaluated both the safety and efficacy of a brief period of transcutaneous supraorbital neurostimulation (tSNS) in a group of patients with migraine without aura (MwoA).
● 81% of patients saw at least a 50% reduction in monthly migraine attacks.
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
Read More
● 81% of patients saw at least a 50% reduction in monthly migraine attacks.
● 75% of patients saw at least a 50% reduction in the number of monthly migraine days.
The sedative effect study: Neurostimulation with CEFALY induces fatigue
In this double-blind cross-over sham-controlled study, researchers observed a statistically significant decrease in vigilance and attention during high-frequency neurostimulation. This can be a positive side effect of CEFALY for people suffering an acute migraine attack.
Read More